Welcome to our dedicated page for Enzon Pharma SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Enzon Pharmaceuticals, Inc. amended its Section 382 Rights Agreement for the ninth time to push the Final Expiration Date to noon, New York City time, on March 18, 2026. The Rights Agreement is otherwise unchanged and the filing recites prior amendments that moved the expiration repeatedly.
The company also issued a press release stating the exchange offer for Series C Preferred Stock now expires at 5:00 p.m., Eastern time, on March 16, 2026, unless further extended. The filing incorporates the Ninth Amendment as Exhibit 4.1 and the press release as Exhibit 99.1.
Enzon Pharmaceuticals, Inc. entered into a Ninth Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date from noon, New York City time, on March 11, 2026, to noon, New York City time, on March 18, 2026. Management states this extension is in the best interests of the company and its stockholders, and all other terms of the rights plan remain unchanged. The company also announced that its exchange offer to swap Series C Non-Convertible Redeemable Preferred Stock for Enzon common stock has been extended to 5:00 p.m. Eastern time on March 16, 2026, unless further extended. The filing also reminds investors that Enzon has filed a Form S-4 registration statement for its proposed merger with Viskase Companies, Inc., which contains detailed information about the combined company.
Enzon Pharmaceuticals amended its Schedule TO to report results and extend its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock. The Company extended the Offer deadline to 5:00 p.m. Eastern Time on March 16, 2026. As of 5:00 p.m. ET on March 10, 2026, 340 shares had been validly tendered and not withdrawn, representing less than 1% of the 40,000 shares outstanding as of that date. Previously scheduled expiration was one minute after 11:59 p.m. ET on March 11, 2026. Holders who already validly tendered need not re-tender.
Enzon Pharmaceuticals announced an extension of its exchange offer to permit holders of its Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. After the extension, the Offer expires one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless the Offer is further extended.
The filing also reminds readers that Enzon filed a Form S-4 registration statement in connection with the proposed merger with Viskase Companies, Inc. and that the Registration Statement and related materials, including financial information for the combined company, are available on www.sec.gov and on Enzon’s website.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock, who may exchange those shares for Enzon common stock. The offer now expires one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless further extended.
The update sits alongside disclosures about Enzon’s proposed merger with Viskase Companies, Inc. and references a previously filed Form S-4 registration statement that includes a prospectus, consent solicitation statement and offer to exchange, as well as detailed risk factors and forward-looking statement warnings for the combined company.
Enzon Pharmaceuticals extended its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock to one minute after 11:59 p.m., Eastern Time, on March 11, 2026. As of 5:00 p.m. ET on March 6, 2026, 339 shares had been validly tendered and not withdrawn, representing less than 1% of the 40,000 shares outstanding as of March 6, 2026.
The Offer exchanges each Series C preferred share for Common Stock at a ratio equal to the share's aggregate liquidation preference divided by $7.83, after giving effect to the Reverse Stock Split; prior terms and conditions remain unchanged.
Enzon Pharmaceuticals, Inc. is registering up to 7,935,878 shares of common stock in connection with the contemplated merger and Series C exchange.
The supplement provides unaudited fiscal year 2025 financial statements for Viskase Companies, Inc., shows Viskase reported a net loss of $65,655 (thousands) for the year ended December 31, 2025, and discloses that the Merger is expected to close in 2026 subject to standard closing conditions and regulatory approvals.
Enzon Pharmaceuticals filed Amendment No. 3 to its Schedule TO to supplement an exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock to exchange each share for Common Stock using an exchange denominator of $7.83 after giving effect to the Reverse Stock Split.
The amendment attaches unaudited consolidated financial statements of Viskase Companies, Inc. for the year ended December 31, 2025 provided in connection with the contemplated merger and the expiration of the Company’s exchange offer. The Viskase statements show total assets of $402,436 (amounts in thousands) and net loss attributable to Viskase of $(65,494) for the year ended December 31, 2025. The Viskase financials include a going concern disclosure tied to refinancing its Senior Credit Facility maturing in August 2026.
Enzon Pharmaceuticals’ 2025 report centers on its planned all‑stock merger with Viskase and continued lack of operating revenue. The company functions as a public company acquisition vehicle, with no employees and no clinical operations, relying mainly on interest income from cash raised in a 2020 rights offering.
In 2025 Enzon generated no royalty or milestone revenue, compared with $26,000 in 2024, and reported an operating loss of $5.3 million, driven by $4.0 million of merger‑related transaction expenses and $1.4 million of general and administrative costs. Interest and dividend income was $1.9 million, down from $2.5 million, leading to a net loss of $3.4 million versus net income of $0.8 million in 2024.
As of December 31, 2025, Enzon held $42.6 million in cash and cash equivalents and had a full valuation allowance against approximately $29.7 million of deferred tax assets, reflecting uncertainty about using its net operating loss carryforwards. A Section 382 rights plan remains in place but must be terminated before the merger closes.
The merger agreement with Viskase, if completed, will combine the companies under the new name “Viskase Holdings, Inc.” and keep the stock quoted on the OTCQB, subject to re‑application. After the merger and related Series C preferred stock exchanges, current Enzon common stockholders are expected to own about 5% of the combined company, Series C holders about 40%, and Viskase stockholders 55%, significantly diluting existing common holders’ voting influence. The report highlights risks around Viskase’s recent operating deterioration, Icahn‑affiliated entities’ anticipated control of roughly 93% of the combined company, potential limits on NOL utilization, and the possibility the merger may not close if conditions such as the Series C exchange offer, minimum $40 million closing cash balance, and timing requirements are not met.
Enzon Pharmaceuticals entered into an Eighth Amendment to its Section 382 Rights Agreement to extend the Final Expiration Date of its rights to noon, New York City time, on March 11, 2026. Except for that extension, the Rights Agreement remains unchanged.
The company also announced an extension of the exchange offer for its Series C Non-Convertible Redeemable Preferred Stock, which now expires one minute after 11:59 p.m., Eastern time, on March 9, 2026, unless further extended. Enzon disclosed that a Registration Statement on Form S-4 has been filed in connection with the proposed merger with Viskase Companies, Inc., and included customary cautionary forward-looking statements and risk factors.